RCC stands for renal cell carcinoma, the most common type of kidney cancer arising from renal tubular epithelium.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
The 2026 ASCO GU Symposium featured significant trial results in renal cell carcinoma, urothelial carcinoma, and prostate cancer, including data from LITESPARK-022, KEYNOTE-B15, SunRISE-2, and PEACE-3 studies.
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07324876 |
A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) |
NOT_YET_RECRUITING | |
| NCT07300241 |
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma |
RECRUITING | PHASE1 |
| NCT06682793 |
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression |
RECRUITING | PHASE1/PHASE2 |
| NCT06585878 |
A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma |
NOT_YET_RECRUITING | NA |
| NCT06577961 |
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT06259552 |
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors |
RECRUITING | PHASE1 |
| NCT05931393 |
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) |
RECRUITING | PHASE2 |
| NCT05917106 |
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) |
RECRUITING | |
| NCT03891485 |
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy |
COMPLETED | |
| NCT03875313 |
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors |
TERMINATED | PHASE1/PHASE2 |
